Combating Antimicrobial Resistance (AMR)
Antimicrobial Resistance (AMR) is a growing health crisis that occurs when bacteria, viruses, fungi, and parasites develop resistance to medications. This makes common infections harder to treat, leading to longer illnesses, higher healthcare costs, and, in severe cases, increased mortality. If not addressed, AMR could make everyday infections and medical procedures much more dangerous, potentially taking us back to a time when even minor injuries could become life-threatening.
The spread of AMR is driven by the overuse and misuse of antibiotics in both healthcare and agriculture. , as well as a lack of new antimicrobial treatments being developed. With fewer effective treatment options and a lack of new antibiotics being developed, the threat continues to grow.
Recognizing the critical importance of addressing AMR, the CHB Group is actively participating in a groundbreaking project to combat this global threat. This initiative brings together experts from various disciplines to develop innovative solutions aimed at reducing the emergence and spread of resistant pathogens. The project focuses on introducing new antimicrobial therapies.
Through its Life Science division, the CHB Group is committed to contributing to the fight against AMR, leveraging its expertise and network to support efforts in safeguarding the effectiveness of antimicrobial therapies for future medical use.